Treatment of Nasal Klebsiella oxytoca Infection

First-Line Treatment Options

The American Academy of Otolaryngology-Head and Neck Surgery recommends amoxicillin-clavulanate as the preferred first-line therapy for nasal K. oxytoca infection due to its broad spectrum of activity against respiratory pathogens including Klebsiella species 1, 2
For adults, the recommended dosage is 1.75-4 g/250 mg per day of amoxicillin-clavulanate 2
Alternative options for patients unable to tolerate amoxicillin-clavulanate include cefpodoxime proxetil 1, 2, cefuroxime axetil 1, 2, and cefdinir 2

If no improvement after 72 hours of initial therapy, consider switching to respiratory fluoroquinolones (levofloxacin, moxifloxacin) 2 or high-dose amoxicillin-clavulanate (4 g/250 mg per day) 2
For severe infections or confirmed resistant strains, consider parenteral therapy with ceftriaxone 1 g/day IM or IV 2

Standard duration of treatment is 7-10 days for most cases 1, 2
Cefuroxime-axetil and cefpodoxime-proxetil have been shown to be effective in 5-day regimens 1
For more severe infections, longer courses may be necessary 2

Intranasal saline irrigation may help alleviate symptoms 3
Intranasal corticosteroids may provide symptomatic relief 3
For patients with significant nasal congestion, consider short-term decongestants 3

Clinical improvement should be expected within 72 hours of appropriate antibiotic therapy 2
If symptoms persist or worsen after 72 hours, consider changing antibiotic therapy based on likely resistance patterns 2, obtaining cultures if not previously done 2, or evaluating for complications or alternative diagnoses 2

For children, appropriate weight-based dosing of amoxicillin-clavulanate should be used, with adequate potassium clavulanate levels to inhibit β-lactamase–producing organisms, as recommended by the American Academy of Pediatrics 4

Recent evidence suggests that the risk of serious allergic reactions to second- and third-generation cephalosporins in patients with penicillin allergy is minimal, according to the American Academy of Pediatrics 4

Parenteral therapy with ceftriaxone (1 g/day IM or IV) may be necessary for patients who are acutely ill, vomiting, or have confirmed resistant strains, as suggested by the American Academy of Pediatrics 4
For hospitalized patients with severe infections, intravenous cefotaxime or ceftriaxone can be initiated, as recommended by the American Academy of Pediatrics 4

If symptoms persist or worsen after 72 hours, consider obtaining cultures if not previously done, as advised by the American Academy of Pediatrics 4
Consulting with an otolaryngologist for possible maxillary sinus aspiration to obtain samples for culture and susceptibility testing may be necessary, according to the American Academy of Pediatrics 4

An alternative approach is to continue antibiotic therapy for 7 days after the patient becomes symptom-free, with a minimum course of 10 days, as suggested by the American Academy of Pediatrics 4